ERBB2 and neoplasm: The recent development of HER2‐targeting ADCs (i.e., trastuzumab emtansine and trastuzumab deruxtecan) could be used as a strategy which the main tumor lesion was treated with NIR‐PIT, and small metastases are with ADC itself.